Greenpeak Partners-backed Certania completed the acquisition of an 85% stake in Bioarray.

Greenpeak Partners-backed Certania, a global group operating in the testing, inspection and certification sector, completed the acquisition of an 85% stake in Bioarray, a Spanish company specializing in clinical genetics and molecular diagnostics. Financial terms were not disclosed. "Bioarray brings cutting-edge genetic testing capabilities to Certania, significantly enhancing our presence in life sciences and clinical diagnostics. Their innovation-driven mindset and international outlook align perfectly with our mission to build a group of exceptional, specialized companies united by quality and scientific excellence," Karsten Xander, Certania CEO and Founder.